Oxford Immunotec Company Overview
|
|
- Evan Cummings
- 5 years ago
- Views:
Transcription
1 Oxfrd Immuntec Cmpany Overview J.P. Mrgan Healthcare Cnference 2019 Oxfrd Immuntec Glbal PLC 94C Innvatin Drive Miltn Park, Abingdn Oxfrdshire, OX14 4RZ, United Kingdm Cmpany Number
2 Frward-Lking Statements Certain infrmatin cntained in this presentatin cnstitutes frward-lking statements, including thse related t anticipated plans and bjectives, future perfrmance and revenues, financial cnditin, prspects, grwth, strategies, expectatins and bjectives f management. Frward-lking statements can be identified by the fact that they d nt relate strictly t histrical r current facts. The financial results and frward-lking statements cntained in this presentatin reflect ur current expectatins and are subject t risks and uncertainties. Actual results may differ materially frm thse prjected r implied by frward-lking statements. Please review ur SEC filings fr mre infrmatin regarding thse factrs that culd cause actual results and events t differ materially frm thse indicated in the frward-lking statements. Our filings are available fr free by visiting the investr sectin f ur website, r the SEC's website, Investrs shuld give careful cnsideratin t these risks and uncertainties. Frward-lking statements cntained herein are based n current expectatins and assumptins and currently available data and are neither predictins nr guarantees f future events r perfrmance. Yu shuld nt place undue reliance n frward-lking statements cntained herein, which speak nly as f the date f this release. We d nt undertake t update r revise any frwardlking statements after they are made, whether as a result f new infrmatin, future events, r therwise, except as required by applicable law. T-SPOT, T-Cell Select, T-Cell Xtend, and the Oxfrd Immuntec lg are trademarks f Oxfrd Immuntec Ltd. 2
3 Glbal, High-Grwth Diagnstics Cmpany Fcused n prprietary assays fr immunlgy and infectius disease Bstn, MA US headquarters US cmmercial peratins US supply chain peratins Oxfrd, UK OUS headquarters OUS cmmercial peratins Manufacturing Prduct develpment UK ODL lab 3 Shanghai, China China market develpment ffice Medical educatin, marketing, technical supprt Ykhama, Japan Japan headquarters Japan cmmercial peratins
4 A Fundamentally Transfrmed Cmpany Divestiture f US service business t Quest Diagnstics fr $170M repsitins cmpany Grwth Fcus Prfitability Optinality Explit the large, grwing and underserved market fr Tuberculsis (TB) screening Dramatically simplified peratins as a pure-play prducts cmpany fcused n TB Materially imprved tp- and bttm- line prfitability Markedly strnger balance sheet 4
5 Tuberculsis: The Wrld s Deadliest Infectin 10,000,000 new cases 1,600,000 deaths Tp 10 cause f death glbally Leading cause f death wrldwide frm a single infectius agent Surce: Glbal Tuberculsis Reprt Geneva: Wrld Health Organizatin (WHO);
6 Reactivatin Tuberculsis Cntrl Relies n Screening fr Latent TB Ending the tuberculsis epidemic will require the eliminatin f this [reservir] f infectin - Wrld Health Organizatin, The End TB Strategy 1.7 billin peple are estimated t have a latent TB infectin Individuals with Latent TB infectin are at risk f develping active TB disease during their lifetime Reinfectin Screening fr TB infectin is a critical element f TB cntrl Prevents future cases prevents future transmissin Surces: Glbal Tuberculsis Reprt Geneva: WHO; The End TB Strategy. Geneva: WHO;
7 TB Screening: A Majr Glbal Market Opprtunity 50M+ Latent TB Infectin (LTBI) screening tests perfrmed each year UN set aggressive gal fr rapid scale up f testing, t get >30 millin peple n preventative treatment by 2022 Surces: Diagnstics fr Tuberculsis: Glbal Demand and Market Ptential. Geneva: WHO; General Assembly reslutin 73/3, Plitical declaratin f the high-level meeting f the General Assembly n the fight against tuberculsis, A/RES/73/3 (10 Octber 2018), available frm undcs.rg/a/res/73/3. 7
8 The Current Screening Test fr TB Tuberculin Skin Test ( TST ) This methd has been in clinical use fr mre than 90 years. Unfrtunately, its applicatin is prblematic due t the frequency f false-psitive and false-negative skin reactins. - Wrld Health Organizatin, Diagnstics fr Tuberculsis Main Limitatins Lw sensitivity, especially in immunsuppressed, newbrns, and elderly Pr specificity due t: Prir BCG vaccinatin Envirnmental mycbacteria Requires a return visit fr reading Inculatin and reading are technique-dependent and require specially-trained peratrs Recurrent supply shrtages f purified prtein derivative (PPD), the test substance used Cllectively these issues result in inefficient use f healthcare resurces Surce: Diagnstics fr Tuberculsis: Glbal Demand and Market Ptential. Geneva: WHO;
9 Market Replacing TST with IGRA Bld Tests Our slutin: T-SPOT.TB Bld test based n immunlgy; generically referred t as an interfern-gamma release assay One f tw recmmended alternatives t TST Superir sensitivity cited in recent guideline updates and publicatins IGRAs have several advantages ver the TST Higher specificity (fewer false psitives) N need fr specifically trained healthcare wrkers N need fr return visit Surces: Glbal Tuberculsis Reprt Geneva: Wrld Health Organizatin (WHO); Lewinshn DM, Lenard MK, LBue PA, Chn DL, Daley CL, et al. Official American Thracic Sciety/Infectius Diseases Sciety f America/Centers fr Disease Cntrl and Preventin Clinical Practice Guidelines: Diagnsis f Tuberculsis in Adults and Children. Clinical Infectius Diseases
10 Significant Cmmercial T-SPOT.TB Adptin CE mark (EU apprval), 1 st EU guideline, US FDA apprval 2010 CDC guidelines issued in US; Chinese SFDA apprval 2011 CPT cde & US Medicare reimbursement established Japanese MHLW apprval & reimbursement established SWITCH health ecnmic study published in US T-SPOT.TB apprved fr sale in >50 cuntries Revised Japanese guidelines 2014 Opened market develpment ffice in China; hired salesfrce in Japan 2015 Exceeded 300m cvered lives in the US UK NHS Tender fr new entrant screening USPTF Grade B recmmendatin & revised ATS/IDSA/CDC guidelines New screening guidelines in Suth Krea & expanded guidelines in China French reimbursement CDC decisin requiring use f IGRA & new WHO latent TB guidelines IGRAs included in first-ever WHO Essential Diagnstics List AAP recmmends use f IGRAs in children as yung as tw years ld 2019 CMS expands reimbursement premium ver cmpetitive IGRA further Surce: Oxfrd Immuntec cmpany reprts 10
11 Yet, Adptin is Still Early Ptential market pprtunity exceeds: TST ~75-80% Market Share IGRAs ~20-25% Market Share Surce: Oxfrd Immuntec analysis 50M+ tests annually Guidelines becming ever mre supprtive f cnversin 11 AAP guidelines n LTBI screening, June 2018 IGRAs t be used even in children as yung as 2 years ld WHO Essential Diagnstics List, May 2018 WHO latent TB guidelines, February 2018 Remve prir recmmendatin against IGRA use in lw and middle incme cuntries CDC instructin t civil surgens, February 2018 TST is n lnger acceptable, must perfrm an IGRA CDC/ATS/IDSA guidelines, December 2016 IGRAs preferred ver TST T-SPOT.TB has superir sensitivity
12 US: The Largest Single Market fr LTBI Screening Principal Screened Ppulatins US Market by Segment Market Segment by Testing Lcatin Segment Size (Tests/Year) Hspitals 7.0M Public & Student Health 1.5M Physicians Offices/Clinics 7.3M Other 1 6.0M TOTAL ~22M Surce: Oxfrd Immuntec analysis 1 Military, Crrectinal Facilities, Chrnic Care Hmes, and Other 12
13 Quest Deal Bradens US Market Access fr T-SPOT.TB By leveraging Quest s reach and capabilities, US market access t T-SPOT.TB will be immediately bradened: Enables unparalleled access t the large physician ffice market segment Helps remve barriers t adptin Gaining an additinal vice in the market 13
14 Outside the US: Grwing Demand fr TB Screening Already strng uptake f IGRAs in develped markets We have a strng business in Eurpe and in Japan where we are the market leader Grwing market as cuntries expand TB screening Significant new prgrams ver past years in UK, Krea, China 2018 WHO latent TB guidelines: prvides mre ptins fr the testing and evaluatin f at-risk ppulatins UN declaratin t get >30 millin peple n TB preventative treatment by 2022 Expand gegraphical channel t meet the demand Grwing presence in Asia, evaluating additinal cuntries & partnerships Surces: WHO; Oxfrd Immuntec estimates Surces: Latent Tuberculsis Infectin: Updated and Cnslidated Guidelines fr Prgrammatic Management. Geneva: WHO; General Assembly reslutin 73/3, Plitical declaratin f the high-level meeting f the General Assembly n the fight against tuberculsis, A/RES/73/3 (10 Octber 2018), available frm undcs.rg/a/res/73/3. 14
15 T-Cell Select: Fully Autmated Slutin & 54-Hur Strage T-Cell Select enables full autmatin f T-SPOT.TB, prviding unrivaled sample stability and simplicity f bld cllectin 54-hur strage at rm temperature Sample Stability Benefits: Lngest sample stability Mst flexible lgistics Expands labratry reach Enables sample batching Autmatin Benefits: Simplifies wrkflw Reduced hands-n time Decreases labr csts Imprves thrughput 15 Surce: Oxfrd Immuntec
16 Our Lnger-Term Strategic Optinality TB Acquire prducts/cmpanies in the TB space t leverage and expand ur cmpetitive psitin Immunlgy Explit ur immunlgy knwhw and inventins in ther markets, acquire cmpanies with cmplementary prducts & channel OXFD tday Channel Leverage ur glbal manufacturing, regulatry and cmmercial channel thrugh acquisitin f entities that can benefit frm this 16
17 Financial Prfile Strng mmentum in TB business Recurring revenue allws us t fcus sales teams primarily n driving grwth Recrd vlumes in Q Brad-based grwth acrss US, Asia, and Eurpe & ROW Significantly enhanced grss margin prfile ~70% grss margins Imprved bttm-line prfitability prfile Reduced OPEX spend as a pure-play prducts cmpany, cmbined with expanded grss margins 1 Pre-Transactin: ttal cmpany grss margins, as reprted fr the year ended Dec 31, 2017 Pst-Transactin: expectatins fr ttal cmpany grss margins fllwing the clse f transactin, as cmmunicated n the 3Q18 earnings call Strng balance sheet ~$200M in cash and n debt, fllwing clse f Quest transactin in Nvember
18 Key Pririties fr 2019 Grwth & Fcus Prfitability Accelerate revenue grwth thrugh strategic cllabratin with Quest Diagnstics, which significantly increases the reach and cmpetitiveness f T-SPOT.TB in the largest market fr TB screening (the US) Grw cmmercial channels utside the US as mre cuntries cmmence and expand TB screening prgrams and t meet rising demand Imprve ur custmer experience thrugh cntinued investment t pull thrugh the benefits f T-Cell Select Cntinued investment in autmatin f ur TB kit manufacturing t reduce COGS Drive perating leverage thrugh dramatically simplified peratins as a pure-play prducts cmpany with ~70% grss margins Optinality Return cash t sharehlders via a $100 millin share purchase prgram 1 1 The share purchase prgram apprved by the Bard f Directrs is subject t sharehlder apprval and will be presented fr sharehlder apprval n r befre the cmpany's annual general meeting f sharehlders n Tuesday, June 18,
19 Summary & Key Investment Highlights Leadership psitin in new class f testing fr wrld s deadliest infectius disease Very large, grwing, underserved market Differentiated, industry-leading immunlgy technlgy Diversified, recurring revenue streams Strng revenue grwth Strng grss margins Pathway t prfitability thrugh expense leverage Strng balance sheet Brad pprtunities t build value in the business 19
Oxford Immunotec Company Overview
Oxfrd Immuntec Cmpany Overview Nvember, 2015 Dr. Peter Wrightn-Smith, Chief Executive Officer Rick Altieri, Chief Financial Officer Oxfrd Immuntec Glbal PLC 94C Innvatin Drive Miltn Park, Abingdn Oxfrdshire,
More informationOxford Immunotec Company Overview
Oxfrd Immuntec Cmpany Overview Nvember 2017 Oxfrd Immuntec Glbal PLC 94C Innvatin Drive Miltn Park, Abingdn Oxfrdshire, OX14 4RZ, United Kingdm Cmpany Number 08654254 www.xfrdimmuntec.cm 1 Frward-lking
More informationOxford Immunotec Company Overview
Oxfrd Immuntec Cmpany Overview August 2017 Dr. Peter Wrightn-Smith, Chief Executive Officer Oxfrd Immuntec Glbal PLC 94C Innvatin Drive Miltn Park, Abingdn Oxfrdshire, OX14 4RZ, United Kingdm Cmpany Number
More informationPress Release. Adocia: Activity and results for the first half of 2013
Press Release Adcia: Activity and results fr the first half f 2013 Intensificatin f R&D activity ahead f the launch f three clinical trials fr insulin prjects, starting in the secnd half f 2013 Net result
More informationPress Release. Adocia Reports Operational and Financial Results for the First Half of 2014
Press Release Adcia Reprts Operatinal and Financial Results fr the First Half f 2014 Majr clinical results reprted n tw frmulatins based n insulin Sund financial psitin with apprximately EUR 16 millin
More informationElectrosurgical Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc
Electrsurgical Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc Grwing awareness regarding mst recent surgical techniques in develping regins is expected
More informationAngiography Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2026 Grand View Research, Inc
Angigraphy Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2026 Grand View Research, Inc The glbal angigraphy devices market size was valued at USD 9.8 billin in 2018 and is prjected
More informationIntravascular Catheters Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc
Intravascular Catheters Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc The glbal intravascular catheters market size was valued at USD 4.1 billin in 2018
More informationREPORT ON OPERATIONS 2017 TELEPHONE CONFERENCE
REPORT ON OPERATIONS 2017 TELEPHONE CONFERENCE NO ONE SHOULD HAVE TO DIE WAITING FOR A NEW ORGAN February 12, 2018 MAGNUS NILSSON, CEO CHRISTOFFER ROSENBLAD, CFO NASDAQ OMX Stckhlm (mid cap): XVIVO HIGHLIGHTS
More informationIntracranial Pressure (ICP) Monitoring Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc
Intracranial Pressure (ICP) Mnitring Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc The glbal intracranial pressure mnitring devices market is expected t
More informationAmniotic Membrane Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc
Amnitic Membrane Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc The glbal amnitic membrane market size was valued at USD 2.26 billin in 2017 and is estimated
More informationSecond Quarter 2009 Results. Analyst and Media Conference July 28, 2009 Zurich
Secnd Quarter 2009 Results Analyst and Media Cnference July 28, 2009 Zurich This presentatin cntains frward lking statements which invlve risks and uncertainties. The actual perfrmance, results and timing
More informationINTERIM REPORT JANUARY SEPTEMBER 2017
INTERIM REPORT JANUARY SEPTEMBER 2017 TELEPHONE CONFERENCE NO ONE SHOULD HAVE TO DIE WAITING FOR A NEW ORGAN Octber 27, 2017 MAGNUS NILSSON, CEO CHRISTOFFER ROSENBLAD, CFO NASDAQ OMX Stckhlm (mid cap):
More informationPancreatic Cancer Treatment Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc
Pancreatic Cancer Treatment Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc The rising prevalence f besity, alchl cnsumptin, and smking is expected t prpel
More informationVirus Filtration Market Size, Share & Trends Analysis Report and Segment Forecast, 2026 Grand View Research, Inc
Virus Filtratin Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2026 Grand View Research, Inc The glbal assisted walking device market is expected t reach ver USD 2.0 billin by 2024 accrding
More informationLEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST
OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED
More informationDigital Patient Monitoring Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2026 Grand View Research, Inc
Digital Patient Mnitring Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2026 Grand View Research, Inc The glbal digital patient mnitring devices market size was valued at USD 38
More informationTranscatheter Embolization And Occlusion Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2026 Grand View Research, Inc
Transcatheter Emblizatin And Occlusin Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2026 Grand View Research, Inc The glbal Transcatheter Emblizatin and Occlusin (TEO) devices
More informationRate Lock Policy. Contents
Rate Lck Plicy Cntents Rate Lcks... 2 Rate Lck Cnfirmatin... 2 Lck Term... 2 Pre-Lck... 2 Maximum Qualified Rate... 3 Extensins... 3 Cst t Extend... 3 Relcks... 4 Re-Negtiatin r Flat Dwn Plicy... 4 Prgram
More information2017 CMS Web Interface
CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationPhotomedicine Devices And Technologies Market Size, Share & Trends Analysis Report and Segment Forecast, 2024 Grand View Research, Inc
Phtmedicine Devices And Technlgies Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2024 Grand View Research, Inc The glbal phtmedicine devices and technlgies market accunted fr USD 314.9
More informationEXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION
EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION The Bitechnlgy Innvatin Organizatin (BIO) and ur member
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-14-1-0444 TITLE: Culd HER2 Hetergeneity Open New Therapeutic Optins in Patients with HER2- Primary Breast Cancer? PRINCIPAL INVESTIGATOR: Gary Ulaner, MD, PhD CONTRACTING ORGANIZATION:
More informationOntario 2018 provincial election issues backgrounder
Ontari 2018 prvincial electin issues backgrunder Dietitians f Canada Pririties May 2018 Access t dietitians in Ontari s health system Diet is the #1 risk factr fr chrnic diseases that cst Ontari $90 billin
More informationIowa Early Periodic Screening, Diagnosis and Treatment Care for Kids Program Provider Training
Iwa Early Peridic Screening, Diagnsis and Treatment Care fr Kids Prgram Prvider Training The Early Peridic Screening, Diagnsis and Treatment (EPSDT) Care fr Kids prgram is Iwa s Medicaid prgram fr children.
More informationRisk factors in health and disease
Risk factrs in health and disease Index 1 Intrductin 2 Types f risk factrs 2.1 Behaviural risk factrs 2.2 Psychlgical risk factrs 2.3 Demgraphic risk factrs 2.4 Envirnmental risk factrs 2.5 Genetic risk
More informationENT Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2022 Grand View Research, Inc
ENT Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2022 Grand View Research, Inc The glbal ENT devices market size was valued at USD 17.2 billin in 2016. It is estimated t prgress
More informationRetinal Surgery Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc
Retinal Surgery Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc The glbal retinal surgery devices market size was estimated at USD 1.56 billin in 2016
More informationTrauma Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc
Trauma Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc The glbal trauma devices market size was valued at arund USD 6.9 billin in 2017 and is anticipated
More informationPresident Chirac understood that fighting disease is not just health systems and hospitals, it is about people. We must place people at the centre.
Michel Sidibé Executive Directr, UNAIDS Speech Opening Ceremny 2016 Wrld Cancer Cngress 31 st Octber 2016, Paris, France Cngratulatins and grateful thanks t the rganizers - Unin fr Internatinal Cancer
More informationIndependent Charitable Patient Assistance Program (IPAP) Code of Ethics
Independent Charitable Patient Assistance Prgram (IPAP) Cde f Ethics Independent charitable patient assistance prgrams (IPAPs) fcus n the needs f patients wh are insured, meet certain financial limitatin
More information18 th Annual Citi Not-for-Profit Health Care Investor Conference. Managing Change
18 th Annual Citi Nt-fr-Prfit Health Care Investr Cnference Managing Change May 24, 2017 Presenters: Richard P. Miller President and Chief Executive Officer Rbert M. Segin Executive Vice President and
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationEndodontic Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2026 Grand View Research, Inc
Enddntic Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2026 Grand View Research, Inc The glbal enddntic devices market size was valued at USD 1.56 billin in 2018 and is expected
More informationA fake medicine that passes itself off as a real, authorised medicine. (1)
Falsified medicines Index 1 Intrductin 2 Types f falsified medicines 3 Eurpean regulatin n falsified medicines 4 Risks f falsified medicines 5 Buying medicine nline safely 6 References 7 Further resurces
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationCLINICAL MEDICAL POLICY
Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019
More informationThe data refer to persons aged between 15 and 54.
Drug-related hspital stays in Australia 1993-2005 Prepared by Amanda Rxburgh and Luisa Degenhardt, Natinal Drug and Alchl Research Centre Funded by the Australian Gvernment Department f Health and Ageing
More information2017 CMS Web Interface
CMS Web Interface PREV-6 (NQF 0034): Clrectal Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationFee Schedule - Home Health Care- 2015
Fee Schedule - Hme Health Care- 2015 01/01/2015 1600 E Century Ave Ste 1 PO Bx 5585 Bismarck ND 58506-5585 www.wrkfrcesafety.cm Cpyright Ntice The five character cdes included in the Nrth Dakta Fee Schedule
More informationA Unified Approach to Conflict Mineral Compliance for the Tungsten Industry. The Westin, Sydney, 23 September 2013
A Unified Apprach t Cnflict Mineral Cmpliance fr the Tungsten Industry The Westin, Sydney, 23 September 2013 Backgrund Cmpliance f public US dwnstream tungsten users with the reprting requirements f the
More information2017 CMS Web Interface
CMS Web Interface CARE-2 (NQF 0101): Falls: Screening fr Future Fall Risk Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION...
More information2018 CMS Web Interface
CMS Web Interface HTN-2 (NQF 0018): Cntrlling High Bld Pressure Measure Steward: NCQA CMS Web Interface V2.0 Page 1 f 18 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE SAMPLING INFORMATION... 4
More informationCHAI Update, February 2013
https://wikileaks.rg/pdesta-emails/emailid/31276 GLOBAL PROGRAM S CHAI UPDATE February2013 Essential Medicines/zinc/ORS CHAI secured $9 millin USD frm NORAD/the Gvernment f Nrway t supprt its zinc-ors
More informationLTCH QUALITY REPORTING PROGRAM
4 LTCH QUALITY REPORTING PROGRAM GENERAL INFORMATION...3 LTCH FACILITY-LEVEL QUALITY MEASURE REPORT...5 LTCH PATIENT-LEVEL QUALITY MEASURE REPORT...18 LTCH REVIEW AND CORRECT REPORT...23 09/2018 v1.04
More informationPandemic H1N1 2009: DrillSafe Update. David Blizzard BD Manager, Energy Mining and Infrastructure
Pandemic H1N1 2009: DrillSafe Update David Blizzard BD Manager, Energy Mining and Infrastructure Pandemic H1N1 Update CDC.Gv USA Pandemic H1N1 Summary Pints Virus cntinues t spread with nearly all WHO
More informationA pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps.
NAU Mdel Observatin Prtcl The mdel prtcl was develped with supprt and expertise frm the Natinal Institute fr Excellence in Teaching (NIET) and is based in great part n NIET s extensive experience cnducting
More informationVaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE
Vaccine Infrmatin Statement: PNEUMOCOCCAL CONJUGATE VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están
More informationTHE DANISH HARM REDUCTION MODEL
THE DANISH HARM REDUCTION MODEL OUTLINE 1. Drug use and drug prblems in Denmark. 2. Danish drug plicy. 3. Danish harm reductin plicy. 4. Drug cnsumptin facilities. DANISH DRUG POLICY Drug plicy can be
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)
Questin GENERAL Why did MHS implement a Medical Specialty Slutins Prgram? Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Managed Health Services (MHS) Answer Effective Nvember
More informationOTHER AND UNSPECIFIED DISORDERS
OPTUM COVERAGE DETERMINATION GUIDELINE OTHER AND UNSPECIFIED DISORDERS Guideline Number: BH727OUD_102017 Effective Date: Octber, 2017 Table f Cntents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationLaw Fellowships in Legal Empowerment
Law Fellwships in Legal Empwerment Abut Namati Namati is dedicated t putting the law in peple s hands. We strive t build a just wrld, in which every ne f us can take part in the decisins and demand accuntability
More informationState Health Improvement Plan Choosing Priorities, Creating a Plan. DHHS DPH - SHIP Priorities (Sept2016) 1
State Health Imprvement Plan 2017-2021 Chsing Pririties, Creating a Plan DHHS DPH - SHIP Pririties (Sept2016) 1 Creating a Plan: 2017-2021 SHIP Welcme! Wh s here? What is the State Health Imprvement Plan
More informationMedical Student Immunization Requirements
Medical Student Immunizatin Requirements The State f Illinis cde, Reference: (110 ILCS 20) Cllege Student Immunizatin Act, requires students t prvide prf f immunity: Measles (Rubela), Mumps, Rubella (German
More informationMalaria 2025: Accelerate to Eliminate The Global Technical Strategy for Malaria: Setting global targets Azra Ghani, GTS Steering Committee
Malaria 2025: Accelerate t Eliminate The Glbal Technical Strategy fr Malaria: 2016-2025 Setting glbal targets Azra Ghani, GTS Steering Cmmittee Geneva, 12 March 2014 1 Visin and Gals Purpse f Visin and
More informationMGPR Training Courses Guide
MGPR Training Curses Guide fiscal cde 92107050921 1. Descriptin The training prgram supprted by MGPR is prpsed by a grup f excellent mentrs/educatrs, accmplished in Pesticides Management and Analysis,
More informationThe Cannabis Act and Regulations
The and Regulatins OVERVIEW The and Regulatins cme int frce n Octber 17, 2018 and replaces the Access t Cannabis fr Medical Purpses Regulatins (ACMPR), and any mentin f Cannabis and Marihuana in the Narctics
More informationHealth Consumers Queensland submission
Health Cnsumers Queensland submissin Inquiry int Public Health (Medicinal Cannabis) Bill 2016 Queensland Parliament Health, Cmmunities, Disability Services and Family Vilence Preventin Cmmittee Cntact:
More informationSwindon Joint Strategic Needs Assessment Bulletin
Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical
More informationContinuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator
Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results
More informationSTANDARD OPERATING PROCEDURES (SOP) EXPANDING THE CONTINUUM OF CARE SATELLITE SITES
STANDARD OPERATING PROCEDURES (SOP) EXPANDING THE CONTINUUM OF CARE SATELLITE SITES 1. Intrductin t Cntinuum f Care In 2003, the Ministry f Health f the Ryal Kingdm f Cambdia apprved the Cntinuum f Care
More informationWorld Confederation for Physical Therapy Congress , May Singapore
Wrld Cnfederatin fr Physical Therapy Cngress 2015 1-4, May Singapre Call fr applicatins fr Chair f the Internatinal Scientific Cmmittee The Executive Cmmittee f WCPT invites applicatins and suggestins
More informationNovel methods and approaches for sensing, evaluating, modulating and regulating mood and emotional states.
Nvel methds and appraches fr sensing, evaluating, mdulating and regulating md and emtinal states. 2018 Jy Academic Grant Call fr Prpsals Intrductin The Annual Jy grant initiative aims t prmte and cntribute
More informationFDA Dietary Supplement cgmp
FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes
More informationResponse to. type 2 vaccine-derived polioviruses. prior to global topv withdrawal. Interim Guidelines
Respnse t type 2 vaccine-derived pliviruses prir t glbal topv withdrawal Interim Guidelines August 2015 GPEI peratinal guidance nte August 2015 Summary Prepare fr prmpt actin fr any area r ppulatin at
More informationPersistence Market Research
Ophthalmic Devices Market - Glbal Study n Ophthalmic Devices: Asia t Witness Highest Grwth by 2020 Persistence Market Research Glbal Ophthalmic Devices Market Will Reach $2,685.1 millin in 2020: Persistence
More informationNew London County Unified Intake for Homeless Families
New Lndn Cunty Unified Intake fr Hmeless Families Presentatin by Lisa Tepper Bates, Executive Directr Mystic Area Shelter & Hspitality (MASH) 2011 Snapsht: Family Hmelessness in Sutheastern CT Frm 2010
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer
More information23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)
Intrductin & Aims Drug and Alchl Cnsultatin Liaisn (AOD CL) services aim t imprve identificatin and treatment f patients with AOD mrbidity. The csts and cnsequences f targeting AOD patients presenting
More informationCancer Association of South Africa (CANSA)
Cancer Assciatin f Suth Africa (CANSA) Fact Sheet and Psitin Statement n Cannabis in Suth Africa Intrductin Cannabis is a drug that cmes frm Indian hemp plants such as Cannabis sativa and Cannabis indica.
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More informationInvestor Update November 2011
Investr Update Nvember 2011 Cmpany Strategy Prject Style Cnventinal High Impact Prjects (ie big prspects: high IP s and large well reserves). Strng 3D prspects with gd analgues prspects are selected based
More informationSafety of HPV vaccination: A FIGO STATEMENT
FIGO Statement n HPV Vaccinatin Safety, August 2nd, 2013 Safety f HPV vaccinatin: A FIGO STATEMENT July, 2013 Human papillmavirus vaccines are used in many cuntries; glbally, mre than 175 millin dses have
More informationFIGHT DEMENTIA ACTION PLAN
FIGHT DEMENTIA ACTION PLAN DEMENTIA IS A HEALTH PRIORITY Dementia will be the majr health prblem f this century. Over ne millin Australians are already affected by the disease themselves r are caring fr
More informationPROPOSAL TO OFFER DOCTOR OF DENTAL MEDICINE DEGREE
Presentatin t Flrida Bard f Gvernrs State University System f Flrida PROPOSAL TO OFFER DOCTOR OF DENTAL MEDICINE DEGREE James H. Ammns, President September 14, 2011 INNOVATIVE COLLEGE OF DENTAL MEDICINE
More information2017 CMS Web Interface
CMS Web Interface Diabetes Mellitus (DM) Cmpsite (All r Nthing Scring) DM-2 (NQF 0059): Diabetes: Hemglbin A1c (HbA1c) Pr Cntrl (>9%) DM-7 (NQF 0055): Diabetes: Eye Exam Measure Steward: NCQA Web Interface
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Luisiana Healthcare Cnnectins Prviders Questin GENERAL Why did Luisiana Healthcare Cnnectins implement a Medical Prgram? Answer
More information2018 CMS Web Interface
CMS Web Interface Diabetes Mellitus (DM) Cmpsite (All r Nthing Scring) DM-2 (NQF 0059): Diabetes: Hemglbin A1c (HbA1c) Pr Cntrl (>9%) DM-7 (NQF Measure Steward: NCQA CMS Web Interface V2.1 Page 1 f 26
More informationThe Shea Supply Chain and its Value in Confectionery Products. GSA New York May 2014
The Shea Supply Chain and its Value in Cnfectinery Prducts. GSA New Yrk May 2014 IOI Lders Crklaan is part f IOI Grup Prperty develpment Oil palm plantatins Olechemicals Edible Oils (including IOI Lders
More informationTO: Mayor & Council DATE: March 8, The Planning & Development Department and the Legal Services Division recommend that Council:
CORPORATE REPORT NO: R049 COUNCIL DATE: March 12, 2018 REGULAR COUNCIL TO: Mayr & Cuncil DATE: March 8, 2018 FROM: SUBJECT: General Manager, Planning & Develpment City Slicitr, Legal Services Cannabis
More informationTASKFORCE REPORT AIMS TO BOOST CANCER SURVIVAL AND TRANSFORM PATIENT EXPERIENCE
Sunday 19 July, 2015 TASKFORCE REPORT AIMS TO BOOST CANCER SURVIVAL AND TRANSFORM PATIENT EXPERIENCE SIX STRATEGIC pririties have tday (Sunday) been recmmended by the Independent Cancer Taskfrce t help
More informationBelgian Volition SA - a VolitionRx Company- Technological company presentation BIOWIN DAY 2014
Belgian Vlitin SA - a VlitinRx Cmpany- Technlgical cmpany presentatin BIOWIN DAY 2014 Abut VlitinRx Wh we are Lab and Head ffice in Namur, Belgium Creatin: Oct 2010 8 emplyees + Internatinal Bard f Directrs
More informationRush Copley Medical Center 2017 Prevention and Screening Initiatives
Cmmunity Needs Assessment Rush Cpley Medical Center 2017 Preventin and Screening Initiatives Rush Cpley Medical Center s (RCMC) main service areas include Kane Cunty and Kendall Cunty, Illinis. The 2014
More information2018 CMS Web Interface
CMS Web Interface PREV-12 (NQF 0418): Preventive Care and Screening: Screening fr Depressin and Measure Steward: CMS CMS Web Interface V2.1 Page 1 f 23 06/25/ Cntents INTRODUCTION... 3 CMS WEB INTERFACE
More informationThe U.S. & The Global Fund to Fight AIDS, Tuberculosis and Malaria
The U.S. & The Glbal Fund t Fight AIDS, Tuberculsis and Malaria The Glbal Fund t Fight AIDS, Tuberculsis and Malaria (Glbal Fund) is an independent, multilateral, financing entity designed t raise significant
More informationAgenda Item 3 CX/FL 17/44/3 Add 1 September 2017
E Agenda Item 3 CX/FL 17/44/3 Add 1 September 2017 1. Intrductin JOINT FAO/WHO FOOD STANDARDS PROGRAMME CODEX COMMITTEE ON FOOD LABELLING 44 th Sessin Asunción, Paraguay, 16 20 Octber 2017 DISCUSSION PAPER
More information2017 CMS Web Interface
CMS Web Interface PREV-12 (NQF 0418): Preventive Care and Screening: Screening fr Depressin and Fllw-Up Measure Steward: CMS Web Interface V1.0 Page 1 f 22 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More information2018 CMS Web Interface
CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.1 Page 1 f 27 06/25/ Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...
More informationHSC 106 Personal Health Plan for Learning Activities & Assessment linked to Michigan Teacher Preparation Standards
HSC 106 Persnal Health Plan fr Learning Activities & Assessment linked t Michigan Teacher Preparatin Standards Standard 1 Cmpetency 1.1 Understand basic health cntent as it relates t schl health educatin.
More information2018 CMS Web Interface
CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.0 Page 1 f 27 11/13/2017 Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...
More informationQUALITY AND SAFETY MEASURES UPDATE January 2016
CLINICAL EFFECTIVENESS/SAFETY M CORE MEASURES 2015 See attached Results QUALITY AND SAFETY MEASURES UPDATE January 2016 Jint Cmmissin and CMS Cre Measure Dashbard updated with mst recent data available:
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationFrontier School of Innovation District Wellness Policy
Frntier Schl f Innvatin 6700 Crprate dr. Suite 150 Phne: 816-363-1907 http://www.kcfsi.rg/ Frntier Schl f Innvatin District Wellness Plicy The Bard prmtes healthy schls, by supprting wellness, gd nutritin,
More informationKey Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.
Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. The United States is currently experiencing a natinwide utbreak f entervirus D68 (EV-D68) assciated with severe
More informationCode of employment practice on infant feeding
Cde f emplyment practice n infant feeding An Emplyer s guide t: Sectin 69Y f the Emplyment Relatins Act 2000 Frewrd As Minister f Labur, I am pleased t publish the Cde f Emplyment Practice n Infant Feeding.
More informationBritish Sign Language (BSL) Plan October 2018 Scottish Charity Regulator
British Sign Language (BSL) Plan 2018-2024 Octber 2018 Scttish Charity Regulatr Cntents Sectin 1: Intrductin and cntext 1.1 Intrductin 1.2 Our wrk and what we d Sectin 2: Our BSL Plan 2.1 Scttish Public
More informationUNIT 2: mapping bananas
Oxfam Educatin www.xfam.rg.uk/educatin UNIT 2: mapping bananas Age range: 7-11 years Outline Learners will investigate sme f the cuntries where the bananas we eat in the UK are grwn. They will first lcate
More informationRecord of Revisions to Patient Tracking Spreadsheet Template
Recrd f Revisins t Patient Tracking Spreadsheet Template Belw is a recrd f revisins made by the AIMS Center t the Patient Tracking Spreadsheet Template. The purpse f this dcument is t infrm spreadsheet
More informationPrimary Prevention for Occupational Health: The Effects of Pollution Prevention (P2) Interventions on Worker Safety and Health in Massachusetts
Primary Preventin fr Occupatinal Health: The Effects f Pllutin Preventin (P2) Interventins n Wrker Safety and Health in Massachusetts Karla Armenti, ScD NH Divisin f Public Health Services TURA 20 th Anniversary
More information